Background {#Sec1}
==========

It was reported that the occurrence of myocardial fibrosis was related to sudden cardiac death and heart failure in patients with HCM. Late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) is a widely used clinical method to detect fibrosis, however, its spatial resolution is limited. The purpose of this feasibility study is to determine the value of T~1~ mapping for the non-invasive assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM).

Methods {#Sec2}
=======

Thirty HCM patients and 20 healthy volunteers underwent conventional late gadolinium enhancement (LGE) imaging and T~1~ mapping (Siemens prototype sequence) on a clinical 1.5T scanner (MAGNETOM Aera, Siemens Healthcare). T~1~ mapping was performed with a modified look-locker inversion-recovery (MOLLI) sequence acquired during breath hold in the same planes after LGE imaging. Typical imaging parameters were: non-selective inversion pulse, steady-state free precession single-shot read out in mid-diastole, FOV of 360 × 250 mm^2^, matrix of 192 × 150, slice thickness of 8 mm, TR/TE of 375.28/1.01 ms, minimum inversion time of 90 ms, inversion time increment of 80 ms, FA of 35^?^, PAT factor of 2, number of inversions 2, images acquired after first inversion 3, pause 3 heart beats, and images acquired after second inversion. T~1~ Mapping was used for measurement of T~1~ values. Global ECV values were calculated from T~1~ maps acquired pre- and post-contrast calibrated by blood hematocrit. The extracellular volume (ECV) value was calculated as: ECV = (1-hematocrit) (1/T1myopost-1/T1myopre) / (1/T1bloodpost-1/T1bloodpre).

Results {#Sec3}
=======

HCM patients had the same age as control group (38.2 ± 18.5 vs. 34.8 ± 15.7, P=NS). Pre-contrast myocardial T~1~ time and myocardial ECV in patients with HCM was significantly higher than the measurement in control cases, and post-contrast myocardial T~1~ time in HCM patients was significantly lower than that in control cases (*P* \< 0.05, respectively) (Table [1](#Tab1){ref-type="table"}, Figure [1](#Fig1){ref-type="fig"}).Table 1T1 measurement and ECV in cases with HCM and in control casesMapping parametersHCMControlP valuePre-contrast T1 value1217.3 ± 97.41143.6 ± 84.30.021Post-contrast T1 value489.3 ± 57.1503.1 ± 64.40.016ECV0.257 ± 0.0360.231 ± 0.0280.009Figure 1

Conclusions {#Sec4}
===========

The MOLLI T~1~ mapping used in the present study has combined the fast acquisition time and multiple contrast capabilities of the TI scout with the improved CNR, spatial resolution, and spatial coverage of the segmented IR LGE scans. The combination reduces the total imaging time, enables T~1~ quantification, and does not compromise image quality. A relatively higher pre-contrast T~1~ value and ECV, and lower post-contrast T~1~ value were found with T~1~ mapping in the myocardium of HCM patients, which suggested T~1~ mapping is better in the evaluation of myocardial fibrosis. The main limitation is that we had a small patient population without subgroup analysis and follow-up.
